Our laboratory is focused on understanding the chromatin remodeling processes that establish the normal epigenetic landscape in developing tissue, how it can be perturbed to promote carcinogenesis, and provide insight for the development of new therapies. We are particularly interested in how the RB pathway, which is altered in virtually every cancer, control epigenetic events that control cell fate specification and differentiation in normal cells – aiming to elucidate the relationship between cell differentiation and tumorigenesis in the absence of the RB family. We are currently studying the role of chromatin remodelers regulated by the RB pathway in the formation of retinal, bone, and lung cancers. Our work will likely influence the development of new therapeutic interventions for retinoblastoma, osteosarcoma, small cell lung cancer, and other cancers with RB pathway inactivation.